Drug intelligence / Profile preview

CELTIC-19

Development stage: Preclinical
Lead developer: Alaya.bio
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies, Nanoparticles → Drug Delivery Systems
Administration: Intravenous

Overview

**CELTIC-19** is Ixaka Ltd.'s lead targeted nanoparticle product (TNP) designed for treating CD19-positive hematological malignancies. It consists of a polymer nanoparticle encapsulating a bald lentiviral vector engineered for CD19 x CD3 targeting, enabling in vivo CAR-T-like gene delivery to T cells without ex vivo manipulation. The product has received Advanced Therapy Medicinal Product (ATMP) classification from the European Medicines Agency, highlighting its innovative approach to bioproduction challenges in cell therapy.[1][5]

Targets

CD19 (B lymphocyte antigen CD19)CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on CELTIC-19.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CELTIC-19.

Explore the full profile